Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04211545 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04211545 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 24 participants.
The verdict
NCT04211545, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, randomized, four-period, crossover study in healthy females of nonchildbearing potential and male subjects - to be conducted at a single center in the United States. The study will consist of a screening phase, a baseline phase, four treatment periods, and a follow-up phone call. The 4 treatment periods are divided into two pairs (Period 1 and 2 and Period 3 and 4), potentially separated by an intermission during which subjects will be discharged from the research unit: Periods 1 and 2 support relative bioavailability (RBA) estimation, while Periods 3 and 4 support estimation of PPI effects.
Interventions
- DRUG Rabeprazole
- DRUG CC-92480
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2019-12-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04211545
The ClinicalTrials.gov registry entry for NCT04211545 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rabeprazole is the first listed.
NCT04211545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04211545 about?
NCT04211545 is a clinical study titled "Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects". This is a Phase 1, open-label, randomized, four-period, crossover study in healthy females of nonchildbearing potential and male subjects - to be conducted at a single center in the United States. The study will consist of a screening phase, a baseline phase, four treatment periods, and a follow-up...
What is the current status of trial NCT04211545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-10-21. Estimated completion is 2019-12-26.
What interventions are being tested in trial NCT04211545?
The interventions under investigation include: Rabeprazole (DRUG), CC-92480 (DRUG).
Who is sponsoring clinical trial NCT04211545?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.